The Markey Cancer Center (MCC), a dedicated matrix cancer center established as an integral part of the University of Kentucky (UK) and the UK Healthcare enterprise, has undergone dramatic expansion in recent years under the leadership of MCC Director Dr. B. Mark Evers. At this point in the center's development, the MCC seeks support through the National Cancer Institute (NCI) Cancer Center Support Grant to capitalize on this momentum and to drive a measurable reduction in cancer mortality in Kentucky, particularly Appalachian Kentucky, through a comprehensive program of cancer research, prevention, and patient care. The need for NCI Cancer Center designation is particularly acute in a state that leads the nation across numerous cancer indicators, including the highest rate of cancer deaths in the nation. Situated on a campus with all six health professions colleges in proximity to each other, the MCC offers a history of rich transdisciplinary collaboration, an outstanding program of cancer prevention and control that has produced seminal work in Appalachian Kentucky, nationally acclaimed basic research programs in cancer biology and DNA repair and oxidative stress, and a translational therapeutics program complemented by a top five College of Pharmacy. These strengths have coalesced in MCC's four thematic research programs: Cancer Cell Biology and Signaling;Cancer Prevention and Control;Drug Discovery, Delivery and Translational Therapeutics;and Redox Injury and Repair. Currently, the MCC's 108 Research and Associate Research members hold appointments in 24 departments in 7 colleges across the university (25 new faculty were recruited in the last 3 years). MCC members hold grants for 144 research projects funded in the annual composite (direct + indirect) amount of more than $30.5 million, of which over $11.3 million (37%) comes from the NCI. Accrual to therapeutic clinical trials has increased over 130% in three years, and MCC assignable space has increased 40%, including a doubling of state-of-the-art research space. In addition, six shared resources facilitate cutting-edge research by providing a robust infrastructure for specialized expertise and advanced methods. They include: Biospecimen and Tissue Procurement;Biostatistics;Cancer Research Informatics;Clinical Research and Data Management;Flow Cytometry and Cell Sorting;and Free Radical Biology in Cancer. The MCC is currently well positioned to take on new challenges and to continue to evolve in key strategic directions that take maximum advantage of these strengths.

Public Health Relevance

As a state with the second highest all-site cancer Incidence rate and the highest rate of cancer deaths in the United States, Kentucky suffers from particularly intractable cancer health challenges. The Markey Cancer Center seeks support to further develop its capacities in cutting-edge science to accelerate bench to bedside translational outcomes, which will reduce this serious health disparity and significantly impact our patients, our state, and the nation through cancer prevention, patient care, and research.

National Institute of Health (NIH)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee B - Comprehensiveness (NCI)
Program Officer
Ciolino, Henry P
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Kentucky
Schools of Medicine
United States
Zip Code
Shi, Jian; Wang, Yifan; Zeng, Lei et al. (2014) Disrupting the interaction of BRD4 with diacetylated Twist suppresses tumorigenesis in basal-like breast cancer. Cancer Cell 25:210-25
Tuna, Halide; Avdiushko, Rita G; Sindhava, Vishal J et al. (2014) Regulation of the mucosal phenotype in dendritic cells by PPAR?: role of tissue microenvironment. J Leukoc Biol 95:471-85
Huang, Yan; Hu, Yin; Liu, Jinze (2014) Piecing the puzzle together: a revisit to transcript reconstruction problem in RNA-seq. BMC Bioinformatics 15 Suppl 9:S3
Chen, Li; Voronovich, Zoya; Clark, Kenneth et al. (2014) Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma. Neuro Oncol 16:1478-83
Barone, Eugenio; Di Domenico, Fabio; Butterfield, D Allan (2014) Statins more than cholesterol lowering agents in Alzheimer disease: their pleiotropic functions as potential therapeutic targets. Biochem Pharmacol 88:605-16
Förster, Sarah; Welleford, Andrew S; Triplett, Judy C et al. (2014) Increased O-GlcNAc levels correlate with decreased O-GlcNAcase levels in Alzheimer disease brain. Biochim Biophys Acta 1842:1333-9
Gilbert, Misty R; Liu, Yinxing; Neltner, Janna et al. (2014) Autophagy and oxidative stress in gliomas with IDH1 mutations. Acta Neuropathol 127:221-33
Farr, Susan A; Ripley, Jessica L; Sultana, Rukhsana et al. (2014) Antisense oligonucleotide against GSK-3? in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med 67:387-95
Cenini, Giovanna; Fiorini, Ada; Sultana, Rukhsana et al. (2014) An investigation of the molecular mechanisms engaged before and after the development of Alzheimer disease neuropathology in Down syndrome: a proteomics approach. Free Radic Biol Med 76:89-95
Liu, Yinxing; Gilbert, Misty R; Kyprianou, Natasha et al. (2014) The tumor suppressor prostate apoptosis response-4 (Par-4) is regulated by mutant IDH1 and kills glioma stem cells. Acta Neuropathol 128:723-32

Showing the most recent 10 out of 17 publications